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Essential epidemiologic and virologic parameters must be measured to provide evidence for 
policy/public health recommendations and mathematical modeling concerning novel influenza A/H1N1 
virus (NIV) infections. Therefore, from April through August of 2009, the authors collected 
nasopharyngeal specimens and information on antiviral medication and symptoms from households 
with NIV infection on a daily basis in Germany. Specimens were analyzed quantitatively by using 
reverse transcriptase-polymerase chain reaction. In 36 households with 83 household contacts, 15 
household contacts became laboratory-confirmed secondary cases of NIV. Among 47 contacts without 
antiviral prophylaxis, 12 became cases (secondary attack rate of 26%), and 1 (8%) of these was 
asymptomatic. The mean and median serial interval were 2.6 and 3 days, respectively (range: 1–3 
days). On average, the authors detected viral RNA copies for 6.6 illness days (treated in time ¼ 5.7 
days, not treated in time ¼ 7.1 days; P ¼ 0.06), but they estimated that most patients cease to excrete 
viable virus by the fifth illness day. Shedding profiles were consistent with the number and severity of 
symptoms. Compared with other nasopharyngeal specimen types, nasal wash was the most sensitive. 
These results support the notion that epidemiologic and virologic characteristics of NIV are in many 
aspects similar to those of seasonal influenza.  
 
 
Abbreviations: CI, confidence interval; NIV, novel influenza A/H1N1 virus; RT-PCR, reverse 
transcriptase-polymerase chain reaction; SAR, secondary household attack rate. 
 
 
In April 2009, novel influenza A/H1N1 virus (NIV) infections were first observed in Mexican and US 
American patients (1). Only weeks later, the virus had spread worldwide and, on June 11th, the World 
Health Organization announced phase 6 of pandemic alertness and thus the start of the 2009 
influenza pandemic (2).  
 
The basic clinical and epidemiologic characteristics of newly emerging pandemic viruses need to be 
assessed quickly, as these have implications on preventive strategies, clinical diagnosis, and 
epidemiologic modeling (3, 4). Regarding seasonal influenza, much of the knowledge on clinical 
manifestation and shedding was gained through experimental studies. Recently, a review of these 
studies has been published (5). Household studies represent another efficient study type that was 
used to examine basic influenza parameters in seasonal influenza, such as the serial interval (6), the 
duration of infectiousness (7), susceptibility and infectiousness of children versus adults (8), and the 
therapeutic and prophylactic effectiveness of neuraminidase inhibitors (9–13).  
 
For NIV, some preliminary information, based on early—albeit limited—data, was already available, 
including generation time (i.e., duration of time between becoming infected and transmitting the virus 
to another person: 1.9 days (14) and 2.5–3 days (15)), serial interval (2.5 days (16), 2.9 days (17), 3 
days (18), 4–5 days (19)), secondary household attack rates in contacts without antiviral prophylaxis 
(7.6% (18) and 26% (20)), and an apparently increased susceptibility of infection for children 
compared with adults (16–18).  
 
We conducted a prospective, observational study of cases with NIV infection and their household 
contacts in Germany during the summer of 2009, in order to contribute information to the clinical and 
epidemiologic characteristics mentioned above.  
 
The present study had been prepared and piloted in the interpandemic era as part of pandemic 
planning with the goal to rapidly collect important information on the properties of the pandemic virus 
upon the occurrence of the first cases in Germany. 
  
Materials and Methods 
 
When the first laboratory-confirmed pandemic cases were reported to the Robert Koch Institute, we 
immediately attempted to contact all case households via their respective state and local health 
departments to obtain verbal consent to conduct the study in the individual household.With a positive 
answer, the Robert Koch Institute sent out epidemiologic teams to the households of the confirmed 
cases. Written informed consent was obtained from all patients and their household members before 
enrollment. Patients and household members were visited either at home or, if hospitalized, in 
hospital. Enrollment lasted from April to August of 2009.  
 
 
Case definition  
 
The household index case was defined as the first person in the household with laboratory-confirmed 
NIV infection or as the first person with respiratory symptoms (without laboratory confirmation) when 
the disease of another person in the household was a laboratory-confirmed NIVinfection. Household 
secondary cases (with disease onset at least 12 hours after the index case) had to be laboratory 
confirmed.  
 
Influenza-like illness was defined as fever plus ‘‘cough or sore throat.’’ All participants aged less than 
14 years were defined as children, and all older participants, as adults. Laboratory confirmation was 
defined as a positive result of any specimen tested for NIV by reverse transcriptasepolymerase chain 
reaction (RT-PCR). We used the term ‘‘viral shedding’’ when RT-PCR detected viral RNA in a 
nasopharyngeal specimen. A household was defined as a domestic unit consisting of the members of 
a family who live together including nonrelatives and intimate partners (modified according to an online 
dictionary (21)). Participants living in one household with the respective index patient were termed 
‘‘household members’’ or ‘‘household contacts.’’ 
 
 
Data and specimen collection 
 
We assessed symptoms and antiviral medication from each household member on a daily basis 
starting from the day of symptom onset of the index case. Early in the study, we obtained the following 
specimens once a day from all household members in the following order: 1) nasal swab, 2) throat 
swab, 3) sputum, 4) throat wash, and 5) nasal wash. As it could only rarely be obtained from the 
participants, sputum was collected only occasionally. Later in the study, when the first results 
regarding the sensitivity of specimen types suggested a higher sensitivity for nasal wash, we took only 
nasal wash as a regular specimen. For the collection of nasal and throat wash, we used 5 mL of 
isotonic saline, which were instilled into the nostril or the mouth, respectively, and afterwards collected 
in a sterile cup (22). Nasal and throat swabs were collected by using virus transport swabs 
(Mastaswab; MAST Diagnostica, Reinfeld, Germany). Sputum was obtained after a deep cough and 
collected in a sterile cup. Samples were stored refrigerated (at a temperature of approximately 5°C) 
and analyzed as soon as possible.  
 
 
Secondary attack rates 
 
Secondary household attack rates (SARs) were calculated as the proportion of household contacts 
without antiviral postexposure prophylaxis becoming a case within 8 days after symptom onset of the 
index case. Households were excluded from calculation of the secondary household attack rate if the 
index case was isolated in the hospital during the period of time relevant for virus transmission. We 
recorded the date of the beginning of treatment (if any) and regarded treatment with neuraminidase 
inhibitors as ‘‘timely’’ if it began within the first 3 days of illness, that is, the day of symptom onset plus 
2 days. As antiviral prophylaxis was not initiated according to a predefined protocol (as would be the 





We defined the serial interval as the number of days between symptom onset of the household index 
case and symptom onset of the first secondary household case. Other secondary household cases 
  
were only included in the calculation of the serial interval if their symptomonset occurred on the same 
day as the first secondary household case. 
 
 
Sensitivity of specimen types 
 
For the calculation of sensitivity of specimen types, a sampling day was called positive on the basis of 
2 conditions: First, all 4 regularly obtained specimens (nasal swab, throat swab, throat wash, nasal 
wash) were collected on that day, and second, at least 1 of those 4 specimens tested positive on that 
day. This led to 28 positive sampling days, which served as the denominator. The numerator changed 
with each specimen type and was defined as the number of positive results in each specimen type. 
The sensitivity of a specimen type was expressed in percent.  
 
 
Viral shedding, viral shedding profile, and symptom profile 
 
The minimal duration of viral shedding in symptomatic patients was defined as the time between 
symptom onset and the last day a RT-PCR–positive specimen was taken. For the calculation of the 
duration of shedding, we excluded asymptomatic study participants and those whose specimens were 
negative in our laboratory.  
 
In order to display summary curves of clinical symptoms over the course of illness, we calculated a 
daily symptom severity score on a 4-level scale from 0 (not present) to 3 (severe) for each of the 
following symptoms: fever/chills, cough, sore throat, and headache/myalgia. Thus, the daily score 
ranged from 0 points (no symptoms) to 12 points (all symptoms with maximum severity). If, at the end 
of the follow-up period, symptom data were missing but the last recorded score was 0, we assumed 
that the respective patient continued to be asymptomatic.  
 
For the assessment of the viral shedding profile, we included participants who were laboratory 
confirmed and had a definite day of symptom onset. If one or more positive test results were followed 
by a final negative test result, we assumed that the following days also were laboratory negative. To 
compare viral load (expressed as the log10 of RNA copies/mL) with the symptom score, we performed 
2 calculations: 1) pooled analysis (for each illness day, we plotted the median of the log10 of RNA 
copies/mL against the median of symptom scores); 2) individual analysis (using a mixed-effect model 
described in ‘‘statistical analysis’’ below, we estimated the proportion of the variance of the log10 of 





Specimens were analyzed for NIV by RT-PCR at the Centre for Biological Safety, Division of Highly 
Pathogenic Microorganisms (ZBS2), at the Robert Koch Institute. RNA was extracted by using either 
the RTP DNA/RNAVirus Mini Kit (Invitek Gesellschaft für Biotechnik & Biodesign mbH, Berlin, 
Germany) or the MagAttract Viral RNA M48 Kit (Qiagen GmbH, Hilden, Germany) according to the 
manufacturer’s suggestions. Details about the polymerase chain reaction protocol, as well as primer 
and probe sequences, are available upon request. Quantitative results were expressed as RNA 
copies/mL. A sample of specimens with a high number of RNA copies/mL was also tested for 
quantification of infectious viruses by using a plaque assay in a MDCKSIAT1 cell culture monolayer 





We used Student’s t test, chi-squared test, and Fisher’s exact test as appropriate. All statistical tests 
were 2 sided, and probability less than 0.05 was considered statistically significant. For the association 
of the daily viral load (RNA copies/mL) with the symptom score, we constructed a linearmixed-effects 
model with random slope and intercept on the individual level (25). Statistical tests were done with 
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We included 36 households with 119 individuals (36 index cases and 83 household contacts). Of the 




Characteristics of cases and noncases 
 
Index cases displayed symptoms (fever, cough, sore throat, and headache/myalgia) more frequently 
than did household secondary cases with or without antiviral prophylaxis (Table 1). For 
headache/myalgia, this difference between index cases and secondary cases without antiviral 
prophylaxis was statistically significant (P ¼ 0.02). Oseltamivir was the only neuraminidase inhibitor 
used in this setting. Three household secondary cases were asymptomatic: 2 (67%) among the 3 
cases with prophylaxis and 1 (8%) among the 12 cases without prophylaxis.  
 
Household index cases were treated more frequently with oseltamivir compared with secondary cases 
who had not received antiviral prophylaxis before their onset of symptoms (56% vs. 25%) (Table 1). 
Two (6%) of 36 household index cases were hospitalized because of severity of illness but recovered; 
none of the 12 symptomatic secondary cases was hospitalized. Cases treated with oseltamivir within 
the first 3 days of illness were more severely ill at symptom onset than those who started oseltamivir 
later or not at all (influenza-like illness in timely treated patients: 93% (13 of 14); influenzalike illness in 
patients without therapy or without timely therapy: 57% (21 of 37)(P ¼ 0.02). There was no apparent 
difference in length of symptomatic disease between the 2 groups (treated timely vs. not timely/not at 
all) as the average symptomscore of both groups dropped to 1 or belowby day 9.  
 
 
Secondary attack rates 
 
The SAR among household contacts who had not received antiviral prophylaxis was 26% (12 of 47). 
The SAR among index cases aged less than 14 years was similar to that among adult index cases (4 
(17%) of 24 vs. 10 (20%) of 49; relative risk ¼ 0.82; P ¼ 0.70). Susceptibility to NIV infection in 
secondary cases did not differ by age, as SAR in secondary cases among children (4 (36%) of 11) 
was not statistically different from that among adults (10 (16%) of 62; relative risk ¼ 2.25; P ¼ 0.12). 





Eight secondary cases provided information for calculation of the serial interval that ranged as follows: 
1 day (1 patient), 2 days (1 patient), 3 days (6 patients). Thus, the median serial interval was 3 days 
(range: 1–3), and the mean was 2.6 days (standard deviation: 0.7).  
 
 
Sensitivity of specimen types 
 
Specimen type sensitivity was determined from 28 positive sampling days with at least 1 of the 4 
specimen types yielding a positive RT-PCR result. Thirteen (46%) of the 28 positive sampling days 
were situated between the second and fifth days of illness, compared with 15 (54%) positive sampling 
days between illness days 6 and 9. Nasal wash yielded the highest sensitivity for detection of NIV (25 
positive nasal wash samples (89%) of 28 positive sampling days, 95% confidence interval (CI): 72, 
98). All other tested materials (nasal swab: 39%, 95% CI: 22, 59; pharyngeal wash: 29%, 95% CI: 13, 




Viral shedding, viral shedding profile, and symptom profile 
 
There was only 1 symptomatic case who was sampled for NIV before symptom onset. This case was 
sampled on the 2 days before symptom onset and tested positive on both days. All other secondary 
cases were sampled the first time on or after the day of symptom onset.  
 
The mean minimal duration of viral shedding was 6.6 days in all symptomatic cases (standard 
deviation: 2.6 days) (Figure 1), 6.3 days in children, and 6.7 days in adults (children vs. adults, P ¼ 
0.66). The mean duration of viral shedding in patients with timely oseltamivir treatment was 5.7 days 
compared with 7.1 days for those without (P ¼ 0.06).  
 
Based on pooled data, the shedding profile corresponded well with the clinical course (Figure 2; Table 
2). At least half of all symptomatic patients returned to a symptom score of 1 by day 6 and became 
asymptomatic by day 9. The lowest viral load values are 2 log10 RNA copies/mL, that is, 100 RNA 
copies/mL.  
 
Analysis of viral load and symptom score by person-day using the mixed-effect model showed that 
51% of the variance of the viral load can be ‘‘explained’’ by allowing the height of the viral load at 
disease onset of each case as well as the slope to vary randomly. Comparison of the log of the RNA 
copies/mL with the log of the plaque-forming units/mL showed that viral load needed to reach levels of 
at least 104 RNA copies/mL before viral culture became positive. It can be roughly estimated that the 







This study presents data concerning aspects of clinical manifestation, viral shedding, and transmission 





All symptoms occurred less frequently in secondary household cases (without antiviral postexposure 
prophylaxis) compared with index cases. Although the number of secondary cases in our sample was 
small, it is likely to give a more accurate picture on the frequency of clinical symptoms and 
asymptomatic infections compared with information retrieved, for example, from surveillance data or—
as in our study—index cases. The reason for this is that our prospective identification of cases among 
household contacts is likely to be less biased by surveillance case definitions and other forms of 
ascertainment biases.  
 
Fever >38°C (67%) and cough (75%) were still the most frequent symptoms in secondary cases 
without antiviral prophylaxis, while sore throat (25%) and headache/myalgia (33%) were observed in 
only about a quarter of them. The World Health Organization case definition for influenza-like illness 
(fever >38°C, as well as cough or sore throat) would have captured only 58% (7 of 12) of secondary 
cases among contacts without prophylaxis in this study.  
 
We found that, among contacts without prophylaxis, 1 (8%) of 12 secondary cases shed virus but did 
not display any symptoms. In a review of volunteer challenge studies of seasonal influenza, about one 
third of infections have been shown to be asymptomatic (5).We may have missed asymptomatic 
shedding if it occurred over a short period of time, because in several households we began sampling 
only several days after the respective index cases’ symptom onset.  
 
 
Secondary attack rates 
 
The household SAR was 26% among contacts who did not receive antiviral prophylaxis. This value is 
identical to that from a study in Kenya (20) and consistent with data published by the World Health 
Organization (15), but it is substantially higher than those reported in studies from Japan (18) (7.6%in 
  
household contacts who did not receive antiviral prophylaxis), the United Kingdom (16) (8.1%), or the 
United States (17) (13%). Treatment of index cases, climate differences, behavioral differences such 
as the use of face masks, and methods of identifying or defining secondary cases may have 
contributed to the differences between these studies and our data. It is known from seasonal influenza 
that SAR can differ by country, season, or study design; published values varied from 6% (26), 
19%(13), and 23%(12) to 38%(27). Although not statistically significant, the increased SAR among 





Within our small sample of secondary household cases, we report a median serial interval of 3.0 days. 
The serial interval indicates how quickly an epidemic can evolve. Thus, it can be an important 
parameter for mathematical modeling. Published estimates on the serial interval of NIV (mean: 2.5 
days (16); mean: 2.6 days (17); median: 3 days (18)), which were calculated by using the same 
methods as applied in this study, resemble our data and are similar to estimates from seasonal 
influenza (6, 28). An exception is the study by Tuite et al. (19) that, by using a heuristic algorithm, 
estimated the serial interval for NIV to be 4–5 days. 
 
 
Sensitivity of specimen types 
 
This study demonstrates that the nasal epithelium appears to be the preferred anatomical location for 
sample collection and that nasal wash appears to be the most sensitive specimen type. Similar results 
have been obtained for seasonal influenza (29, 30). The substantial difference between nasal wash 
and the other specimen types in our study may have been enhanced by the fact that the majority of 
specimens used for the analysis of specimen type sensitivity were taken on the sixth day of illness or 
later, that is, on days when viral load was already low. If measured on the first days of illness, the 
probability to detect viral shedding may have been substantially higher in specimen types other than 
nasal wash and, thus, the difference between the sensitivities of various sampling methods may have 
been smaller.  
 
 
Viral shedding, viral shedding profile, and symptom profile 
 
The duration of viral shedding depends largely on 3 factors: 1) type of laboratory test (RT-PCR vs. 
viral culture), 2) age, and 3) treatment with antiviral medication. We detected viral RNA copies, on 
average, for 6.6 illness days, assuming that viral shedding starts with illness onset. This result is in 
agreement with that of Cao et al. (31), who found a median shedding duration of 6 days also while 
using polymerase chain reaction. We analyzed our data regarding the association of antiviral 
medication and age on the duration of viral shedding. Duration of shedding might be reduced by about 
1.5 days when treatment is started ‘‘on time’’ (7.1 days vs. 5.7 days). Although this difference was not 
statistically significant (P ¼ 0.06), it must be taken into consideration that most of the cases who were 
treated within the first 3 illness days were index cases who tended to be more severely ill and started 
from a higher viral load. In our small data set, there was no apparent difference in age. In contrast, 
other studies on NIV have identified younger age as a risk factor for prolonged shedding (31, 32).  
 
Our polymerase chain reaction data show that the detection limit is reached when samples contain 
less than 100 RNA copies/mL, whereas virus titration in cell culture starts to identify viruses in 
specimens with at least 10,000 RNA copies/mL. Our results suggest that viable (infectious) viruses 
cease to be present from the fifth illness day. This is in line with data from To et al. (32), while another 
study found that 24% of samples on illness day 7 still contained viable virus (33). This estimate 
compares well with data from seasonal influenza viruses, where the duration of shedding in untreated 
adult volunteers using viral culture was found to last for 4.8 days (5).  
 
Comparison of the clinical course (expressed as symptom score) with viral load demonstrated that 
these 2 curves correlate well. This close correlation is well known from experimental studies in 
seasonal influenza (5) but has—to our knowledge—not yet been demonstrated for NIV. Nevertheless, 
individual data can, of course, differ markedly, which is shown by the fact that only 51% of the 
variance in viral load is ‘‘explained’’ by variations in symptom scores. We both observed substantial 
viral shedding while the patient showed mild clinical illness and also measured low or no viral loads 
despite typical influenza-like clinical presentation.  
  
 
There are several limitations to this study. First, despite the proactive logistical setup of our study, we 
still had difficulties in collecting samples during the very first days of symptoms. Second, because of 
limited laboratory capacity, we sometimes had to stop taking further samples, although the last sample 
later turned out to be positive for NIV. Finally, although we had conducted a large number of 
prospective and labor-intensive field investigations, the study population was limited.  
 
Our study provides systematically acquired observational data addressing several important questions 
on clinical manifestation, probability of transmission, duration of shedding and the possible effect of 
antiviral therapy, the preferred anatomical sampling site, the most sensitive specimen type, and the 
relation of shedding and clinical course in NIV. Overall, our study results do not seem to differ from 
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Tables and Figures 
 
Table 1. Demographic, Clinical, and Treatment Characteristics Among Index Cases, Secondary 


















 N % N % N % N % 
Male sex - n, (%) 18 (50) 1 (33) 3 (25) 31 (46) 
Child (<14 yrs) – n, (%) 7 (19) 1 (33) 4 (33) 7 (10) 
Clinical symptoms          
None- n, (%) 0 (0) 2 (67) 1 (8) NA NA 
Fever > 38°C        n, 
(%) 
29 (81) 0 (0) 8 (67) NA NA 
Cough- n, (%) 34 (94) 1 (33) 9 (75) NA NA 
Sore throat-n, (%) 20 (56) 0 (0) 3 (25) NA NA 
Headache/myalgia 
n, (%) 
27 b (75) 0 (0) 4 b (33) NA NA 
Influenza-like illness 
(Fever and [cough 
or sore throat]) - n, 
(%) 
27 (75) 0 (0) 7 (58) NA NA 
Hospitalisation- n, (%) 11 (31) 0 (0) 3 (25) NA NA 
For isolation 
purposes- n, (%) 
9 (25) NA NA 3 (25) NA NA 
Due to severity of 
illness - n, (%) 
2 (6) NA NA 0 (0) NA NA 
Treatment with Oseltamivir- 
n, (%) 
20 (56) 0 (0) 3 (25) NA NA 
Within the first three 
days of illness - n, 
(%) 
11 (31) NA NA 3 (25) NA NA 
Prophylaxis with Oseltamivir 
- n, (%) 
NA NA 3 (100) 0 (0) 27 (40) 
Chronic disease - n, (%) 6 (17) 0 (0) 3 (25) 9 (22) 
Asthma- n, (%) 4 (11) NA NA 1 (8) 1 (1) 
Cardiovascular 
disease- n, (%) 
1 (3) NA NA 2 (17) 4 (6) 













Table 2. Number of data points, median and quartiles of symptom scores and log10 RNA copies/ml for 
each illness day. 
 
Illness day N Median Lower quartile Upper quartile N Median Lower quartile Upper quartile
1 40 2 1 4.5 3 4.81 2.00 8.33
2 38 4 2 5 6 5.22 4.42 6.55
3 38 3 1 5 11 4.64 3.54 5.81
4 40 2 1 4 20 4.49 3.73 5.44
5 39 2 1 3 27 3.84 2.80 4.37
6 38 1 1 2 30 3.57 2.00 4.43
7 38 1 1 2 32 3.28 2.00 4.26
8 34 1 0 2 31 2.00 2.00 3.21
9 31 0 0 1 33 2.00 2.00 2.00
10 30 0 0 1 34 2.00 2.00 2.00




Figure 1. Minimal duration of viral shedding in symptomatic cases (mean and 95% confidence 
interval), Germany, summer 2009. Minimal duration of shedding is shown for all symptomatic cases, 
as well as stratified by both therapy (timely antiviral therapy ¼ start of treatment within the first 3 days 
of illness; no (or no timely) antiviral therapy ¼ start of treatment later than the third day of illness or not 
at all) and age (children vs. adults). P values were calculated for comparisons between strata of 
therapy (timely therapy vs. no (or no timely) therapy, P ¼ 0.06) and age (children vs. adults, P ¼ 0.66) 















Figure 2. Comparison between clinical severity score (median and quartiles; dashed line) and viral 
shedding profile (median and quartiles of RNA copies/mL, log10; continuous line), Germany, summer 
2009. Note that the y-axis starts at the value of 2 (polymerase chain reaction detection limit). 
 
 
 
  
